CCND1 and breast cancer: Immunoblotting results showed that the expression of cyclin D1 in all three subtypes of breast cancer cells was not dramatically altered by ω-3 FFAs, ATRA and combination of ω-3 FFAs/ATRA treatment (Fig. 2b and Supplementary Fig. S2b).